Search clinical trials for: Camrelizumab and Apatinib

Total 271541 results

Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer
Sun Yat-sen University

Active, not recruiting

PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma (DIPPER)

Nasopharyngeal Neoplasms

China
Shanghai Minimally Invasive Surgery Center

Suspended

A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer

Gastric Cancer

China
Bukwang Pharmaceutical

Completed

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

Gastric Cancer

Korea, Republic of
Fujian Cancer Hospital

Unknown

Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens (ASGARD)

Advanced Metastatic Gastric Cancer
Guilin Medical University, China
Wuzhou Red Cross Hospital; Guangxi Naxishan Hospital; National Hospital of Guangxi...

Unknown

Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
The Affiliated Hospital of the Chinese Academy...

Unknown

Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer

Hepatocellular Carcinoma | Gastric Cancer

China
Tongji University

Unknown

The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy

Gastric Cancer

China
Peking Union Medical College Hospital

Recruiting

A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

Small Cell Lung Carcinoma

China
Novartis Pharmaceuticals

Active, not recruiting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

United States, China, Hungary, Japan, Belgium, Germany, Canada, Singapore, Australia, Israel, Netherlands, Spain, Italy, Korea, Republic of, Bulgaria, France, United Kingdom, Czechia, Sweden, India, Malaysia, Denmark, Taiwan, Norway, Fi... and more
Qilu Hospital of Shandong University

Not yet recruiting

The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

Ovarian Cancer Recurrent
Xiaohua Wu MD

Not yet recruiting

Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

Relapsed Ovarian Cancer
The First Affiliated Hospital of Xiamen University

Not yet recruiting

Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial

Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Carcinoma, Non-Small-Cell Lung

China
West China Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

Lung Cancer | Non Small Cell Lung Cancer | Apatinib | Combination Chemotherapy

China
Fudan University

Recruiting

Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract

Malignant Melanoma

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Completed

Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

Breast Cancer

China
Henan Cancer Hospital

Unknown

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Advanced Cancer | Mucosal Melanoma | Apatinib | SHR-1210

China
Shanxi Province Cancer Hospital

Unknown

Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer

Brain Metastases
Zhejiang Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

Gastric Cancer

China
Ruijin Hospital

Recruiting

BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (BIOVAS)

Sarcoma

China
First Affiliated Hospital Bengbu Medical College

Unknown

Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer

Gastric Cancer | Apatinib | Biomarker

China
Tongji University

Unknown

Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Yue Han
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

Unresectable Hepatocellular Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy

Non-small Cell Lung Cancer

China
Tianjin Medical University Second Hospital

Unknown

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

Small Cell Lung Cancer Extensive Stage

China
Peking University People's Hospital
Peking University Shougang Hospital; Peking University International Hospital

Withdrawn

Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial

Advanced Cancer | Soft Tissue Sarcoma Adult

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Lung Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

NSCLC

China
Changzhou Cancer Hospital of Soochow University

Completed

An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (EASE)

Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

China
Elevar Therapeutics

Completed

A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

Healthy

United States
Peking University Cancer Hospital & Institute

Unknown

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Melanoma

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

Cervical Cancer

China
Fudan University

Recruiting

Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Completed

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Wei Jiang
Wuzhou Red Cross Hospital; Laibin People's Hospital; Guangxi Naxishan Hospital; People's Hospital of Lingshan

Completed

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hospital of Stomatology, Wuhan University
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma (NEOPBOSCC)

Oral Squamous Cell Carcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Head and Neck Squamous Cell Carcinoma

China
Wuhan Union Hospital, China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

Rectal Cancer

China
Augusta University
H. Jean Khoury Cure CML Consortium

Recruiting

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (ALERTCML)

Leukemia, Myeloid | Chronic Myeloid Leukemia, Chronic Phase | Adult CML | Leukemia,Myeloid, Chronic

United States
Wei Zhao
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Hematological Neoplasms

China
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma

Gastric Cancer

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma (SHR-1210)

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Hepatocellular Carcinoma

China
Yan Li
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer

Breast Cancer
Hebei Medical University Fourth Hospital

Unknown

A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma

Refractory or Metastatic Esophageal Squamous Cell Carcinoma

China
Chinese PLA General Hospital

Unknown

The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer

Gastric Cancer

China

3

Subscribe